These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33034163)

  • 1. Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.
    Klonoff DC; Bassock S; Dwyer A; Engels E; Qvist M; Sparre T; Snitker S
    J Diabetes Investig; 2021 Jun; 12(6):978-987. PubMed ID: 33034163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
    Klonoff DC; Bassock S; Engels E; Frederiksen M; Marber M; Qvist M; Sparre T; Snitker S
    Diabetes Obes Metab; 2021 Nov; 23(11):2590-2594. PubMed ID: 34338402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
    Fujioka K; Sparre T; Sun LY; Krogsgaard S; Kushner RF
    J Diabetes Sci Technol; 2015 Jul; 10(1):164-74. PubMed ID: 26183599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
    LaRue S; Malloy J
    J Diabetes Sci Technol; 2015 Jul; 9(4):815-21. PubMed ID: 25759181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usability engineering study in the European Union of a redesigned follitropin alfa pen injector for infertility treatment.
    Jeannerot F; Stüdeli T; Gunther-LaVergne L; Hirning D; Schertz J
    Expert Opin Drug Deliv; 2016 Sep; 13(9):1221-9. PubMed ID: 27329677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing.
    Schertz JC; Saunders H; Hecker C; Lang B; Arriagada P
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1111-20. PubMed ID: 21843107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals.
    Antoszyk AN; Baker C; Calzada J; Cummings H; So J; Quezada-Ruiz C; Haskova Z
    PDA J Pharm Sci Technol; 2018; 72(4):411-419. PubMed ID: 29853609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference.
    Kahr Rasmussen N; Berg B; Christiansen ASL; Neergaard JS; Ter-Borch G; Hildebrand EA; Gonczi M; Sparre T
    Patient Prefer Adherence; 2024; 18():1713-1727. PubMed ID: 39161804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.
    Zijlstra E; Coester HV; Heise T; Plum-Mörschel L; Rasmussen O; Rikte T; Pedersen LK; Qvist M; Sparre T
    Diabetes Obes Metab; 2018 May; 20(5):1140-1147. PubMed ID: 29369493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US human factors engineering evaluation of an updated follitropin alfa pen injector (GONAL-f® RFF Redi-ject®) and instructions for use.
    Mahony M; Dwyer A; Barkume R; Strochlic A; Jeannerot F; Stüdeli T
    Expert Opin Drug Deliv; 2018 Jan; 15(1):5-15. PubMed ID: 29198148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.
    LaRue S; Springer J; Noderer M; Meehan J; Wysham CH
    J Diabetes Sci Technol; 2019 Mar; 13(2):226-234. PubMed ID: 30234374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
    Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D
    J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formative usability evaluation of a fixed-dose pen-injector platform device.
    Lange J; Nemeth T
    Med Devices (Auckl); 2018; 11():105-112. PubMed ID: 29670411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study.
    Andre A; Squittieri N; Patil SB
    Adv Ther; 2021 Jun; 38(6):3129-3142. PubMed ID: 33948925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
    Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
    J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Accuracy, Injection Force, and Usability Assessment of a New Half-Unit, Prefilled Insulin Pen.
    Kappes CM; Kershner JR; Morwick TM; Corrigan SM
    J Diabetes Sci Technol; 2018 Mar; 12(2):364-372. PubMed ID: 29084452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usability of devices for self-injection: results of a formative study on a new disposable pen injector.
    Lange J; Richard P; Bradley N
    Med Devices (Auckl); 2014; 7():195-203. PubMed ID: 24966698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study.
    Andre A; Squittieri N; Patil S
    Endocr Pract; 2022 Apr; 28(4):414-419. PubMed ID: 35123070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.